{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:35Z","timestamp":1792785995909,"version":"4.5.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012665","name":"ICES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ontario Ministry of Health"},{"name":"Ministry of Long-Term Care","id":[{"id":"https:\/\/ror.org\/0320egb26","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioid exposure during cancer treatment is common and leads to new persistent opioid use (NPOU) in a subset of patients. There are limited data on the incidence and predictors of NPOU among patients with diffuse large B-cell lymphoma (DLBCL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a population-based cohort study including patients with DLBCL \u226518\u2009years old from Ontario, Canada who received first-line rituximab-based chemoimmunotherapy from 2014 to 2021 and survived &amp;gt;365\u2009days after treatment. We defined opioid exposure as filling \u22651 opioid prescriptions between 90\u2009days prior to and 180\u2009days after first chemoimmunotherapy (index date). The primary outcome was NPOU defined as filling \u22651 opioid prescriptions within both 181-360\u2009days and 361-545\u2009days after index. We used a multivariable modified Poisson regression model to assess the relative risk (RR) of NPOU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our cohort consisted of 4988 patients with DLBCL with a median age of 66\u2009years. Opioid exposure occurred in 55.0% of patients. 6.7% of patients fulfilled criteria for NPOU, including 10.4% of exposed patients compared to 2.4% of unexposed patients. In the multivariable analysis, exposed patients were 4 times more likely to develop NPOU (RR 3.79, 95% CI = 2.85 to 5.06). Other predictors of NPOU included relapsed\/refractory disease, palliative care utilization, prior mental health diagnoses, and high-dose vs low-dose opioid exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More than 1 in 2 DLBCL patients were exposed to opioids during treatment and 1 in 10 exposed patients developed NPOU. Our study identified several predictors of NPOU in DLBCL, which may enable clinicians to identify high-risk patients who would benefit from early intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djag305","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:19:21Z","timestamp":1788297561000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the incidence and predictors of chronic opioid use in early survivorship for patients with diffuse large B-cell lymphoma"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4473-8248","authenticated-orcid":false,"given":"Mithunan","family":"Ravindran","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-807X","authenticated-orcid":false,"given":"Jonathan S","family":"Zipursky","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Sunnybrook Research Institute , Toronto, ON,","place":["Canada"]},{"name":"ICES , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Luo","sequence":"additional","affiliation":[{"name":"ICES , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-475X","authenticated-orcid":false,"given":"Ning","family":"Liu","sequence":"additional","affiliation":[{"name":"ICES , Toronto, ON,","place":["Canada"]},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-3057","authenticated-orcid":false,"given":"Kelvin K W","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Sunnybrook Research Institute , Toronto, ON,","place":["Canada"]},{"name":"ICES , Toronto, ON,","place":["Canada"]},{"name":"Sunnybrook Odette Cancer Centre Division of Hematology\/Oncology, , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Sunnybrook Research Institute , Toronto, ON,","place":["Canada"]},{"name":"ICES , Toronto, ON,","place":["Canada"]},{"name":"Sunnybrook Odette Cancer Centre Division of Hematology\/Oncology, , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-3849","authenticated-orcid":false,"given":"Lee","family":"Mozessohn","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Sunnybrook Research Institute , Toronto, ON,","place":["Canada"]},{"name":"ICES , Toronto, ON,","place":["Canada"]},{"name":"Sunnybrook Odette Cancer Centre Division of Hematology\/Oncology, , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026100511272443700_djag305-B1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/jnci\/djab082","article-title":"Predictors of chronic opioid use: a population-level analysis of North Carolina cancer survivors using multi-payer claims","volume":"113","author":"Check","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026100511272443700_djag305-B2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/djad206","article-title":"Trends in new and persistent opioid use in older adults with and without cancer","volume":"116","author":"Baum","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026100511272443700_djag305-B3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/jnci\/djz200","article-title":"Predicting persistent opioid use, abuse, and toxicity among cancer survivors","volume":"112","author":"Vitzthum","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2026100511272443700_djag305-B4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/cncr.32593","article-title":"New-onset persistent opioid use following breast cancer treatment in older adult women","volume":"126","author":"Roberts","year":"2020","journal-title":"Cancer"},{"key":"2026100511272443700_djag305-B5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/jgs.15945","article-title":"Long-term opioid therapy in older cancer survivors: a retrospective cohort study","volume":"67","author":"Shah","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2026100511272443700_djag305-B6","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1097\/SLA.0000000000005109","article-title":"Outcomes and healthcare utilization among new persistent opioid users and nonopioid users after curative-intent surgery for cancer","volume":"277","author":"Lin","year":"2023","journal-title":"Ann Surg"},{"key":"2026100511272443700_djag305-B7","doi-asserted-by":"publisher","first-page":"e2016858","DOI":"10.1001\/jamanetworkopen.2020.16858","article-title":"Association of current opioid use with serious adverse events among older adult survivors of breast cancer","volume":"3","author":"Winn","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026100511272443700_djag305-B8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2026100511272443700_djag305-B9","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026100511272443700_djag305-B10","doi-asserted-by":"publisher","first-page":"e24448","DOI":"10.7759\/cureus.24448","article-title":"Predictors and long-term outcomes for diffuse large B-cell lymphoma (DLBCL) patients undergoing surgery prior to systemic therapy: a nationwide analysis","volume":"14","author":"Vusqa","year":"2022","journal-title":"Cureus"},{"key":"2026100511272443700_djag305-B11","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2013.52.5188","article-title":"Principles of opioid use in cancer pain","volume":"32","author":"Portenoy","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026100511272443700_djag305-B12","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1200\/JCO.2022.40.16_suppl.6585","article-title":"Persistent high-risk opioid use in lymphoma survivors following treatment","volume":"40","author":"Stafford","year":"2022","journal-title":"JCO"},{"key":"2026100511272443700_djag305-B13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1177\/10781552231210788","article-title":"Patterns of prescription opioid use and opioid-related harms among adult patients with hematologic malignancies","volume":"30","author":"Nabulsi","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"2026100511272443700_djag305-B14","doi-asserted-by":"publisher","first-page":"10732748241290769","DOI":"10.1177\/10732748241290769","article-title":"Prescription opioid use before and after diagnosis of cancer among older cancer survivors with non-cancer chronic pain conditions (NCPCs): an application of group-based trajectory modeling (GBTM)","volume":"31","author":"Safarudin","year":"2024","journal-title":"Cancer Control"},{"key":"2026100511272443700_djag305-B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1476-072X-9-21","article-title":"Feasibility and utility of mapping disease risk at the neighbourhood level within a Canadian public health unit: an ecological study","volume":"9","author":"Holowaty","year":"2010","journal-title":"Int J Health Geogr"},{"key":"2026100511272443700_djag305-B16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2022.6278","article-title":"Postoperative restrictive opioid protocols and durable changes in opioid prescribing and chronic opioid use","volume":"9","author":"Zsiros","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026100511272443700_djag305-B17","doi-asserted-by":"publisher","first-page":"e2234671","DOI":"10.1001\/jamanetworkopen.2022.34671","article-title":"Opioid dose trajectories and associations with mortality, opioid use disorder, continued opioid therapy, and health plan disenrollment","volume":"5","author":"Binswanger","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026100511272443700_djag305-B18","doi-asserted-by":"publisher","DOI":"10.23889\/ijpds.v3i4.644","article-title":"Linking the narcotics monitoring system database to quantify the contribution of prescribed and non-prescribed opioids to opioid overdoses in Ontario, Canada","volume":"3","author":"Martins","year":"2018","journal-title":"Int J Popul Data Sci"},{"key":"2026100511272443700_djag305-B19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/MLR.0b013e318215d5e2","article-title":"Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada","volume":"49","author":"Austin","year":"2011","journal-title":"Med Care"},{"key":"2026100511272443700_djag305-B20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.17269\/s41997-021-00552-1","article-title":"The 2011 and 2016 iterations of the Ontario Marginalization Index: updates, consistency and a cross-sectional study of health outcome associations","volume":"113","author":"van Ingen","year":"2022","journal-title":"Can J Public Health"},{"key":"2026100511272443700_djag305-B21","doi-asserted-by":"publisher","first-page":"E1319","DOI":"10.1503\/cmaj.180368","article-title":"Mental health outcomes after major trauma in Ontario: a population-based analysis","volume":"190","author":"Evans","year":"2018","journal-title":"CMAJ"},{"key":"2026100511272443700_djag305-B22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2352-4642(26)00040-4","article-title":"Psychiatric disorder diagnoses and adverse psychiatric outcomes among pregnant and postpartum adolescents in Ontario, Canada: a retrospective, population-based cohort study","volume":"10","author":"Barker","year":"2026","journal-title":"Lancet Child Adolesc Health"},{"key":"2026100511272443700_djag305-B23","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.29485","article-title":"Impact of aggressive management and palliative care on cancer costs in the final month of life","volume":"121","author":"Cheung","year":"2015","journal-title":"Cancer"},{"key":"2026100511272443700_djag305-B24","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"2026100511272443700_djag305-B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC Guideline for prescribing opioids for chronic pain - United States, 2016","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"2026100511272443700_djag305-B26","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"2026100511272443700_djag305-B27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/jnci\/djad149","article-title":"Mortality among patients with diffuse large B-cell lymphoma and mental disorders: a population-based study","volume":"115","author":"Gong","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2026100511272443700_djag305-B28","doi-asserted-by":"publisher","first-page":"e530","DOI":"10.1016\/S2352-3026(23)00094-7","article-title":"Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study","volume":"10","author":"Kuczmarski","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026100511272443700_djag305-B29","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","article-title":"Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline","volume":"41","author":"Paice","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026100511272443700_djag305-B30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1182\/hematology.2020000100","article-title":"Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas","volume":"2020","author":"Odejide","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026100511272443700_djag305-B31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/rheumatology\/keaa758","article-title":"Socioeconomic status and occurrence of chronic pain: a meta-analysis","volume":"60","author":"Prego-Dom\u00ednguez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026100511272443700_djag305-B32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pmn.2019.08.005","article-title":"Racial and socioeconomic factors associated with the use of complementary and alternative modalities for pain in cancer outpatients: an integrative review","volume":"21","author":"Ludwick","year":"2020","journal-title":"Pain Manag Nurs"},{"key":"2026100511272443700_djag305-B33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/10428194.2024.2306463","article-title":"The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study","volume":"65","author":"Arya","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"2026100511272443700_djag305-B34","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3324\/haematol.2016.152918","article-title":"Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role?","volume":"102","author":"Le Guyader-Peyrou","year":"2017","journal-title":"Haematologica"},{"key":"2026100511272443700_djag305-B35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.canep.2017.04.009","article-title":"No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status","volume":"48","author":"Boslooper","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"2026100511272443700_djag305-B36","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1097\/ALN.0000000000003265","article-title":"Persistent postoperative opioid use: a systematic literature search of definitions and population-based cohort study","volume":"132","author":"Jivraj","year":"2020","journal-title":"Anesthesiology"},{"key":"2026100511272443700_djag305-B37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.addbeh.2018.11.043","article-title":"Association between tobacco smoking and opioid use: a meta-analysis","volume":"92","author":"Rajabi","year":"2019","journal-title":"Addict Behav"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag305\/70896158\/djag305.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag305\/70896158\/djag305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:27:30Z","timestamp":1791214050000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djag305\/8778783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":37,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag305","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"djag305"}}